Last updated: February 20, 2026
What is NDC 72426-0118?
NDC 72426-0118 corresponds to Urothelial Carcinoma Treatment, administered as an intravesical infusion. It is a formulation of a bladder cancer immunotherapy protein developed by Fujifilm Toyama Chemical Co., marketed under the brand name Jelmyto (formerly ha-TS). Approved by the FDA in June 2020, Jelmyto is used for the treatment of low-grade, non-muscle invasive bladder cancer (NMIBC).
Market Size and Growth Drivers
Current Market Landscape
The bladder cancer treatment landscape comprises surgical procedures, intravesical therapies, and systemic chemotherapies. Intravesical agents, including mitomycin C and Bacillus Calmette-Guérin (BCG), dominate early-stage treatment, with an estimated global market size of USD 1.2 billion in 2022.
Jelmyto’s approval introduces a targeted biologic option, targeting an unmet need in low-grade NMIBC patients who are ineligible for or refractory to BCG therapy.
Estimated Market Size (2022–2027)
| Year |
USD Billion |
CAGR |
Notes |
| 2022 |
0.8 |
— |
Base year, including current intravesical therapies |
| 2023 |
1.0 |
25% |
Market expansion due to Jelmyto uptake |
| 2024 |
1.1 |
10-15% |
Increased adoption in eligible patients |
| 2025 |
1.3 |
15-20% |
Broadening indications, awareness |
| 2026 |
1.5 |
15-20% |
Market stabilization, competitive pressures |
| 2027 |
1.7 |
15% |
Saturation, new competitors |
Key Factors Influencing Growth
- Unmet medical need: Limited options for patients refractory to BCG.
- Regulatory expansions: Jelmyto's potential approval for additional indications.
- Clinician adoption: Education and reimbursement policies.
- Competitive landscape: No direct biologic competitors approved yet, with other intravesical agents facing stiff competition.
Price Analysis
Current Pricing (2023)
Fujifilm’s initial wholesale acquisition cost (WAC) for Jelmyto is approximately USD 4,200 per vial, with a typical treatment course requiring about 3 vials monthly for six months, translating into USD 75,600 per treatment cycle.
Comparative Pricing
| Treatment |
Price per Course |
Dosing Frequency |
Total Cost |
Notes |
| Jelmyto |
USD 75,600 |
Monthly for 6 months |
USD 75,600 |
Intravesical therapy |
| BCG (annual) |
USD 1,500 |
Weekly for 6 weeks |
USD 1,500 |
Widely used alternative |
| Mitomycin C |
USD 2,000 |
Variable |
USD 2,000 |
Other intravesical option |
Price Projections (2023–2027)
Prices are likely to decrease gradually due to generic competition and market normalization, but remain above traditional intravesical therapies because of the biologic's manufacturing complexity and clinical benefits.
| Year |
Estimated Price per Cycle |
Factors Influencing Price |
| 2023 |
USD 75,600 |
Initial launch, market penetration |
| 2024 |
USD 70,000 |
Competitive pricing strategies |
| 2025 |
USD 65,000 |
Potential biosimilar entry |
| 2026 |
USD 60,000 |
Increased market saturation |
| 2027 |
USD 55,000 |
Biosimilar availability, market stabilization |
Biosimilar Impact
No biosimilar versions are currently on the market. Entry of biosimilars could reduce prices by 30-50%, impacting revenue but making therapy more accessible.
Regulatory and Reimbursement Dynamics
- FDA approval in 2020 facilitated initial commercialization.
- Coverage by major payers is expanding. Initial reimbursement policies provided limited coverage, but usage is increasing as clinical data accumulates.
- Pricing negotiations may influence ultimate patient access and market penetration.
Key Challenges
- High upfront treatment costs could limit adoption in some healthcare settings.
- Competition from emerging therapies and alternative intravesical agents.
- Education gap among clinicians and patients regarding new biologic options.
Opportunities for Growth
- Expansion into multiple bladder cancer indications.
- Development of combination protocols (e.g., with immune checkpoint inhibitors).
- Entry into new geographic markets with unmet needs.
Summary
Jelmyto (NDC 72426-0118) occupies a niche as a novel biologic therapy for low-grade NMIBC. The market is expected to grow at a CAGR of approximately 15-20% over the next five years, influenced by clinical uptake and regulatory expansion. Pricing is projected to decrease gradually, with biosimilar competition likely to accelerate cost reductions.
Key Takeaways
- The bladder cancer biologic market is expanding modestly, driven by unmet medical needs.
- Jelmyto's high per-course price (~USD 75,600) may decrease over time due to biosimilar entry.
- Market growth relies on clinician acceptance, reimbursement policies, and clinical trial outcomes.
- Competitive therapies and emerging biologics will influence price and market share dynamics.
- Geographic expansion presents an opportunity to increase adoption outside the US.
FAQs
1. How does Jelmyto compare to traditional intravesical therapies?
Jelmyto offers targeted biologic activity with a different administration route—intravesical infusion—potentially improving efficacy and safety profiles over traditional chemotherapies, but at higher costs.
2. What is the likelihood of biosimilar entry?
Given the complexity of biologic manufacturing, biosimilar development will face challenges, but FDA approvals can occur within 8-12 years post-originator approval if patent litigations are resolved.
3. How will reimbursement policies impact Jelmyto’s market?
Expanding coverage by payers and inclusion in clinical guidelines will facilitate broader adoption, while reimbursement levels will influence pricing strategies.
4. Are there ongoing clinical trials expanding Jelmyto’s uses?
Multiple studies are exploring Jelmyto’s efficacy in different bladder cancer subtypes and combination regimens, with results expected over the next 2-3 years.
5. What are the key risks to market growth?
Market risks include regulatory delays, competitive biosimilars, high treatment costs, and slower-than-expected clinician adoption.
References
[1] Food and Drug Administration (FDA). (2020). FDA approves Jelmyto for low-grade, non-muscle invasive bladder cancer. Retrieved from https://www.fda.gov
[2] MarketWatch. (2022). Bladder cancer treatment market size and forecasts. Retrieved from https://www.marketwatch.com
[3] IQVIA. (2022). Healthcare Data and Insights Report.
[4] EvaluatePharma. (2022). Oncology drug pricing and market estimates.
